Develops epigenetics-based clinical tests for cardiovascular disease.
Jun 2026Revenue $14.4K/yrExpenses $6.47M/yr
No trend
Figures by year
When will Cardio Diagnostics Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $14.4K and expenses $6.47M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $14.8K | $6.50M | −$6.48M |
| Dec 2024 | $34.9K | $8.40M | −$8.37M |
| Dec 2023 | $17.1K | $7.26M | −$7.24M |
| Dec 2022 | $950 | $4.55M | −$4.55M |
| Dec 2021 | $901 | $621K | −$620K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.